1.无锡市中医医院,江苏 无锡 214071
2.江苏省中医院,南京 210029
3.南京医科大学 第二附属医院,南京 210011
过俊杰,硕士,住院中医师,从事泌尿外科中西医结合临床研究,E-mail:981797165@qq.com
朱清毅,主任医师,教授,博士生导师,从事泌尿系统肿瘤的微创治疗,E-mail:drzhuqingy@126.com
收稿:2023-08-12,
网络出版:2023-12-18,
纸质出版:2024-02-20
移动端阅览
过俊杰,章茂森,朱清毅.清心滋肾汤对前列腺癌内分泌治疗后潮热的疗效及初步机制研究[J].中国实验方剂学杂志,2024,30(04):152-158.
GUO Junjie,ZHANG Maosen,ZHU Qingyi.Clinical Efficacy of Qingxin Zishen Decoction on Hot Flashes After Endocrine Therapy for Prostate Cancer and Its Preliminary Mechanism[J].Chinese Journal of Experimental Traditional Medical Formulae,2024,30(04):152-158.
过俊杰,章茂森,朱清毅.清心滋肾汤对前列腺癌内分泌治疗后潮热的疗效及初步机制研究[J].中国实验方剂学杂志,2024,30(04):152-158. DOI: 10.13422/j.cnki.syfjx.20240993.
GUO Junjie,ZHANG Maosen,ZHU Qingyi.Clinical Efficacy of Qingxin Zishen Decoction on Hot Flashes After Endocrine Therapy for Prostate Cancer and Its Preliminary Mechanism[J].Chinese Journal of Experimental Traditional Medical Formulae,2024,30(04):152-158. DOI: 10.13422/j.cnki.syfjx.20240993.
目的
2
观察清心滋肾汤对前列腺癌内分泌治疗后潮热症状的临床疗效,初步探讨其疗效机制。
方法
2
收集2021年12月至2022年12月就诊于江苏省中医院符合标准的患者共60例,随机分为观察组与对照组各30例,观察组予清心滋肾汤治疗,对照组予常规护理,观察周期为8周。观察两组患者治疗前后潮热频率、潮热程度、潮热评分、中老年男性睾酮缺乏症状自我测量表(ISS量表)评分和中医证候积分的改善情况,对比治疗前后血清内皮素-1(ET-1)、一氧化氮(NO)和降钙素基因相关肽(CGRP)及前列腺特异抗原(PSA)、睾酮的水平变化。
结果
2
在疗效方面,与本组治疗前比较,观察组患者潮热频率下降,潮热程度减轻,潮热评分降低,ISS量表评分降低,中医证候积分下降(
P
<
0.05);与对照组治疗后比较,观察组患者各项指标均优于对照组(
P
<
0.05)。在实验室指标方面,与本组治疗前比较,观察组患者血清NO水平升高,ET-1水平降低,ET-1/NO下降,CGRP水平降低(
P
<
0.05),而睾酮、PSA水平差异无统计学意义;治疗后观察组患者血清NO水平高于对照组,ET-1水平、ET-1/NO、CGRP水平低于对照组(
P
<
0.05),但两组患者睾酮、PSA水平差异无统计学意义。
结论
2
清心滋肾汤能显著改善前列腺癌患者内分泌治疗后潮热症状,其机制可能是通过调节血管舒缩因子的表达水平,改善血管舒缩功能,从而达到治疗潮热的目的。
Objective
2
To observe the clinical effect of Qingxin Zishen decoction on hot flashes after endocrine therapy for prostate cancer and explore its therapeutic mechanism.
Method
2
A total of 60 patients who met the criteria and were admitted to Jiangsu Province Hospital of Chinese Medicine from December 2021 to December 2022 were collected and randomly divided into a treatment group and a control group, with 30 cases in each group. The treatment group was treated with Qingxin Zishen decoction, while the control group was only given routine nursing. The observation period of this study was eight weeks. The improvement of hot flash frequency, hot flash degree, hot flash score, ISS score, and TCM syndrome score were observed in the two groups before and after treatment. The changes of serum endothelin-1 (ET-1), nitric oxide (NO), calcitonin gene-related peptide (CGRP), prostate specific antigen (PSA), and testosterone were detected.
Result
2
In terms of efficacy, after treatment, the frequency, degree, and score of hot flashes, ISS score, and TCM syndrome score decreased in the treatment group (
P
<
0.05). Compared with the control group, all indicators were better in the treatment group (
P
<
0.05). In terms of laboratory indicators, after treatment, the serum NO level in the treatment group was increased. ET-1 level was decreased. The ratio of ET-1/NO was decreased, and the CGRP level was decreased (
P
<
0.05). However, testosterone and PSA levels were not significantly changed . Compared with the control group, after treatment, the serum NO level in the treatment group was higher, and the level of ET-1 was lower. The ratio of ET-1/NO and the CGRP level were lower (
P
<
0.05). There were no significant differences in testosterone and PSA levels between the two groups.
Conclusion
2
Qingxin Zishen decoction can significantly improve hot flashes in patients with prostate cancer after endocrine therapy. The mechanism of Qingxin Zishen decoction may be to improve the vasomotor function by regulating the expression level of vasomotor factors, so as to treat hot flashes.
孙颖浩 , 杨悦 . 前列腺癌内分泌治疗的现状与展望 [J]. 实用医院临床杂志 , 2017 , 14 ( 6 ): 1 - 4 .
周致远 , 韩邦旻 , 杨博宇 . 前列腺癌雄激素剥夺治疗的危害及防治策略 [J]. 中华医学杂志 , 2020 , 100 ( 34 ): 2641 - 2644 .
ZARZOUR A , SHEVACH J W , MORGANS A K . Adverse effects of androgen deprivation in elderly men with prostate cancer [J]. Curr Geriatr Rep , 2019 , doi: 10.1007/s13670-019-00303-8 http://dx.doi.org/10.1007/s13670-019-00303-8 .
PATIL T , BERNARD B . Complications of androgen deprivation therapy in men with prostate cancer [J]. Oncology(Williston Park) , 2018 , 32 ( 9 ): 470 - 474 .
KAPLAN M , MAHON S M , LUBEJKO B G , et al . Hot flashes:Clinical summary of the ONS Guidelines™ for cancer treatment-related hot flashes in women with breast cancer and men with prostate cancer [J]. Clin J Oncol Nurs , 2020 , 24 ( 4 ): 430 - 433 .
TAYLOR A P , LEE H , WEBB M L , et al . Effects of testosterone and estradiol deficiency on vasomotor symptoms in hypogonadal men [J]. J Clin Endocrinol Metab , 2016 , 101 ( 9 ): 3479 - 3486 .
VILAR G S , MONTAÑÁ P F , VILLAS S M , et al . Physiopathological mechanism of hot flushes-perspiration induced by androgen deprivation in prostate carcinoma [J]. Actas Urol Esp , 2009 , 33 ( 3 ): 235 - 241 .
JONES J M , KOHLI M , LOPRINZI C L . Androgen deprivation therapy-associated vasomotor symptoms [J]. Asian J Androl , 2012 , 14 ( 2 ): 193 - 197 .
RAJAN P , THARAKAN T , CHEN R . Safety of androgen therapy in men with prostate cancer [J]. Best Pract Res Clin Endocrinol Metab , 2022 , 36 ( 5 ): 101628 .
陆莹 , 刘筱迪 , 牛潇菲 , 等 . 中医对减轻前列腺癌内分泌治疗相关潮热的研究进展 [J]. 空军军医大学学报 , 2022 , 43 ( 2 ): 230 - 234 .
陈浩然 , 刘浩 . 从调理中医心-肝-肾轴论治前列腺癌去势综合征 [J]. 世界中医药 , 2021 , 16 ( 21 ): 3250 - 3255 .
张明 , 齐进春 . 2019版 中国泌尿外科前列腺癌诊断治疗指南更新要点解读 [J]. 河北医科大学学报 , 2021 , 42 ( 10 ): 1117 - 1122 .
国家标准化管理委员会 , 国家市场监督管理总局 . 中医临床诊疗术语第2部分·证候 : GB/T16751.2-2021 [S]. 北京 , 2021 .
GUTTUSO T , DIGRAZIO W J , REDDY S Y . Review of hot flash diaries [J]. Maturitas , 2012 , 71 ( 3 ): 213 - 216 .
张志航 , PIMOLSETTAPUN JITTIKORN , 郁超 , 等 . 上海市中心城区中老年男性不育症中医证型分布及临床特征初探 [J]. 上海中医药杂志 , 2020 , 54 ( 10 ): 24 - 28 .
郑筱萸 . 中药新药临床研究指导原则 [M]. 北京 : 中国医药科技出版社 , 2002 : 236 .
SUNG H , FERLAY J , SIEGEL R L , et al . Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin , 2021 , 71 ( 3 ): 209 - 249 .
中国医促会泌尿健康促进分会 , 中国研究型医院学会泌尿外科学专业委员会 . 前列腺癌经典内分泌治疗安全共识 [J]. 现代泌尿外科杂志 , 2018 , 23 ( 4 ): 248 - 258 .
朱旭东 , 杨明 , 叶和松 , 等 . 基于倾向性评分法探讨金水相生方对晚期前列腺癌临床结局的影响 [J]. 中国实验方剂学杂志 , 2022 , 28 ( 17 ): 84 - 90 .
余本坚 , 朱文静 , 王名杨 , 等 . 温肾法防治前列腺癌骨转移的研究进展 [J]. 世界中医药 , 2021 , 16 ( 5 ): 840 - 843 .
KINNAIRD W , MEHTA A , GUO C , et al . The management of hot flushes for men treated with androgen deprivation therapy for prostate cancer:A survey of UK practice [J]. Acupunct Med , 2021 , 39 ( 4 ): 394 - 395 .
李小江 , 冯梦晗 , 牟睿宇 , 等 . 中医药干预前列腺癌内分泌治疗后部分雄激素缺乏综合征的研究进展 [J]. 天津中医药 , 2020 , 37 ( 7 ): 831 - 835 .
贾英杰 , 李小江 , 杨佩颖 , 等 . 中医外治法治疗前列腺癌的研究进展 [J]. 中医肿瘤学杂志 , 2021 , 3 ( 5 ): 83 - 87,93 .
胡荣魁 , 谈勇 . 从清心滋肾汤浅析夏桂成治疗更年期综合征的临床经验 [J]. 南京中医药大学学报 , 2014 , 30 ( 4 ): 373 - 375 .
过俊杰 , 左文仁 , 黄卫周 , 等 . 徐福松从心肾论治前列腺癌去势治疗后诸症经验 [J]. 中医杂志 , 2023 , 64 ( 15 ): 1530 - 1533,1555 .
LUO B , LI Y , WANG W , et al . Clinical evidence and mechanisms of traditional chinese medicine in major diseases [J]. Sci Tradit Chin Med , 2023 , 1 ( 1 ): 3 - 13 .
杨清明 , 邱厚兵 , 贺江 , 等 . 加味温胆汤联合氯沙坦钾治疗原发性高血压的疗效及对血清MMP9、NO、ET-1水平的影响 [J]. 四川中医 , 2022 , 40 ( 10 ): 81 - 84 .
RUSSELL F A , KING R , SMILLIE S J , et al . Calcitonin gene-related peptide:physiology and pathophysiology [J]. Physiol Rev , 2014 , 94 ( 4 ): 1099 - 1142 .
HAY D L , POYNER D R . Calcitonin gene-related peptide,adrenomedullin and flushing [J]. Maturitas , 2009 , 64 ( 2 ): 104 - 108 .
0
浏览量
83
下载量
1
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621
